Veracyte director Karin Eastham sells 14,850 shares

Q: How many VCYT shares did Karin Eastham sell, and at what price?

Karin Eastham sold 14,850 VCYT shares on October 27, 2026, at a weighted average price of $50.0049 per share, with reported prices ranging from $50.00 to $50.05. The sale was made under a Rule 10b5-1 plan adopted May 28, 2026.

The option exercise and stock sale were made under a Rule 10b5-1 plan adopted May 28, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Karin Eastham, a director of Veracyte, exercised fully vested stock options covering 10,000 shares on October 27, 2026, at an exercise price of $27.01 per share, acquiring 10,000 common shares. She also sold 14,850 shares that day at a weighted average price of $50.0049 per share; reported sale prices ranged from $50.00 to $50.05. The transactions were made pursuant to a Rule 10b5-1 plan adopted May 28, 2026. The filing reports zero options following the exercise.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider EASTHAM KARIN

Role Director

Sold 14,850 shs ($743K)

Approx. gross sale proceeds $743K

Approx. exercise cost $270K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F3}	10,000	$0.00	$0.00
Exercise	Common Stock ^F1	10,000	$27.01	$270K
Sale	Common Stock ^{F1, F2}	14,850	$50.0049	$743K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 10,247 shares (Direct)

Footnotes (3)

F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2026.
F2. Represents the weighted average sales price. Sales prices for the transactions range from $50.00 to $50.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F3. The option is fully vested.

Key Figures

Options exercised: 10,000 shares Exercise price: $27.01 per share Common shares acquired: 10,000 shares +4 more

7 metrics

Options exercised 10,000 shares October 27, 2026

Exercise price $27.01 per share Options exercised October 27, 2026

Common shares acquired 10,000 shares October 27, 2026

Shares sold 14,850 shares October 27, 2026

Weighted average sales price $50.0049 per share Sale on October 27, 2026

Reported sale price range $50.00 to $50.05 per share Sale on October 27, 2026

Options following exercise 0 shares Reported after the October 27, 2026 exercise

Key Terms

Rule 10b5-1 plan, weighted average sales price, fully vested

3 terms

Rule 10b5-1 plan regulatory

"pursuant to a Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"Represents the weighted average sales price."

fully vested financial

"The option is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VCYT shares did Karin Eastham sell, and at what price?

Karin Eastham sold 14,850 VCYT shares on October 27, 2026, at a weighted average price of $50.0049 per share, with reported prices ranging from $50.00 to $50.05. The sale was made under a Rule 10b5-1 plan adopted May 28, 2026.

How many VCYT options did Karin Eastham exercise, and at what price?

Karin Eastham exercised fully vested stock options covering 10,000 shares on October 27, 2026, at an exercise price of $27.01 per share, acquiring 10,000 common shares. The filing reports zero options following the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/28/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EASTHAM KARIN

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/27/2026		M⁽¹⁾		10,000	A	$27.01	25,097	D
Common Stock	10/27/2026		S⁽¹⁾		14,850	D	$50.0049⁽²⁾	10,247	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$27.01	10/27/2026		M⁽¹⁾			10,000	⁽³⁾	06/11/2029	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 28, 2026.

2. Represents the weighted average sales price. Sales prices for the transactions range from $50.00 to $50.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. The option is fully vested.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR